Skip to content

US · RFL · REAL ESTATE - SERVICES

Rafael Holdings, Inc. (RFL) intrinsic value and stock valuation

$0.92as of 2026-11-21 · Mkt cap 103.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rafael Holdings, Inc. DCF and intrinsic value

InvestorsCraft values RFL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RFL’s statements →

Rafael Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Real Estate · Real Estate - Services Newark, NJ 07102 rafaelholdings.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$920K-28.5% 5y CAGRd
20152025
Net income
-$-30.52M
20152025
Free cash flow
-$-18.93M
20152025
Total equity
$98.4M-5.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$920K$640K$280K$410K$800K
Operating income-$-26.11M-$-102.63M-$-15.04M-$-60.48M-$-21.2M
Net income-$-30.52M-$-34.41M-$-1.88M-$-124.66M-$-24.54M
EPSd-$-1.04M-$-1.45M-$-80.83K-$-6.31M-$-1.49M
Operating cash flow-$-18.92M-$-7.8M-$-10.89M-$-26.08M-$-15.6M
Capital expenditure-$0.00-$-180K$51.7M-$0.00-$-210K
Free cash flow-$-18.93M-$-7.98M$40.8M-$-26.08M-$-15.81M
Total assets$114.1M$96.8M$98.8M$118.3M$154.1M
Total debt$690K$2.39M$0.00$15M$14.5M
Net debt-$-52.08M-$-290K-$-21.5M-$-11.54M$6.67M
Total equity$98.4M$86.3M$96.6M$97.2M$136.7M
Cash and short-term investments$52.8M$65.9M$79.5M$63.2M$7.85M
Income statement
20252024202320222021
Revenue$920K$640K$280K$410K$800K
Cost of revenue$420K$150K$0.00$0.00$70K
Gross profit$490K$480K$280K$410K$800K
Research and development expenses$12.8M$94M$6.31M$8.74M$4.91M
Selling, general and administrative expenses$13.8M$8.85M$8.93M$17M$20.4M
Other expenses$0.00$230K$80K$35.2M$3.68M
Operating expenses$26.6M$103.1M$15.3M$60.9M$29M
Cost and expenses$27M$103.3M$15.3M$60.9M$29M
Interest income$2M$2.38M$3.25M$200K$0.00
Interest expense$660K$250K$0.00$10K$10K
Depreciation and amortization$290K$230K$80K$70K$70K
Ebitda-$-32.25M-$-66.79M-$-8.67M-$-139.89M-$-23.34M
Operating income-$-26.11M-$-102.63M-$-15.04M-$-60.48M-$-21.2M
Total other income/expenses, net-$-7.09M$34.9M$6.09M-$-80.07M$5.16M
Income before tax-$-33.2M-$-67.68M-$-8.95M-$-140.55M-$-23.04M
Income tax expense-$-2.55M-$-2.68M-$-260K$0.00$20K
Net income-$-30.52M-$-34.41M-$-1.88M-$-124.66M-$-24.54M
Weighted average shares outstanding$29.4M$23.8M$23.3M$19.8M$16.5M
Weighted average diluted shares outstanding$29.4M$23.8M$23.3M$19.8M$16.5M
Balance sheet
20252024202320222021
Cash and short-term investments$52.8M$65.9M$79.5M$63.2M$7.85M
Net receivables$1.83M$6.13M$2.52M$300K$830K
Inventory$280K$0.00$0.00$0.00$0.00
Total current assets$56.7M$72.5M$82.9M$108.4M$14.8M
Property, plant and equipment, net$1.6M$2.12M$1.7M$1.77M$1.84M
Goodwill and intangible assets$52.5M$4.9M$1.57M$1.57M$1.57M
Long-term investments$1.86M$12M$7.62M$480K$80.2M
Total non-current assets$57.4M$24.3M$15.9M$9.97M$139.3M
Total assets$114.1M$96.8M$98.8M$118.3M$154.1M
Accounts payable$6.89M$2.56M$330K$560K$1.16M
Short-term debt$610K$2.31M$0.00$15M$14.5M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.6M$7.51M$2.15M$21M$17.3M
Long-term debt$80K$70K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.14M$3.06M$60K$90K$50K
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$15.7M$10.6M$2.2M$21.1M$17.4M
Common stock$520K$250K$240K$240K$180K
Retained earnings-$-232.26M-$-201.74M-$-167.33M-$-165.46M-$-40.8M
Accumulated other comprehensive income (loss)$4.14M$110K$3.37M$3.7M$3.77M
Total equity$98.4M$86.3M$96.6M$97.2M$136.7M
Total investments$1.86M$75.3M$65.6M$37.2M$80.2M
Total debt$690K$2.39M$0.00$15M$14.5M
Net debt-$-52.08M-$-290K-$-21.5M-$-11.54M$6.67M
Cash flow statement
20252024202320222021
Net income-$-30.64M-$-65M-$-2.21M-$-140.55M-$-22.84M
Depreciation and amortization$290K$230K$80K$70K$70K
Stock-based compensation$2.12M$2.3M$2.19M-$-920K$6.63M
Change in working capital$970K-$-610K-$-90K-$-10K-$-990K
Accounts receivable$90K-$-290K-$-120K$70K-$-160K
Inventory-$-10K$0.00$0.00$0.00$0.00
Accounts payable-$-920K-$-150K-$-830K$50K$160K
Net cash provided by operating activities-$-18.92M-$-7.8M-$-10.89M-$-26.08M-$-15.6M
Investments in property, plant and equipment-$0.00-$-140K$51.7M-$0.00$0.00
Acquisitions, net$0.00$2.35M-$-5.1M$0.00$4.61M
Net cash used for investing activities$44M-$-10.82M$21.2M-$-63.8M-$-7.26M
Common stock issued$25M$0.00$0.00$110.2M$15.1M
Common stock repurchased$0.00-$-170K-$-220K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24.8M-$-180K-$-15.22M$103.9M$29.4M
Net change in cash$50.1M-$-18.82M-$-5.04M$13.7M$6.65M
Cash at end of period$52.8M$2.67M$21.5M$26.5M$12.9M
Operating cash flow-$-18.92M-$-7.8M-$-10.89M-$-26.08M-$-15.6M
Capital expenditure-$0.00-$-180K$51.7M-$0.00-$-210K
Free cash flow-$-18.93M-$-7.98M$40.8M-$-26.08M-$-15.81M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rafael Holdings, Inc.

        Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

        CEO
        Howard S. Jonas
        Employees
        23
        Beta
        0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Rafael Holdings, Inc. (RFL)?

        InvestorsCraft does not currently publish an intrinsic value for RFL. How the IC value is calculated.

        Is RFL undervalued?

        InvestorsCraft does not publish an undervaluation signal for RFL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.